Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.

Bishwas ChamlingMichael BietenbeckDennis KorthalsStefanos DrakosVolker VehofPhilipp StallingClaudia MeierAli Yilmaz

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2022)

As expected, tafamidis does not improve cardiac phenotype in patients with ATTRwt-CM after one year of therapy. However, tafamidis seems to slow down cardiac disease progression in patients with ATTRwt-CM compared to those without tafamidis therapy based on multi-parametric CMR data already after one year of therapy.

Keyphrases

magnetic resonance
wild type
left ventricular
heart failure
high resolution
computed tomography
magnetic resonance imaging
stem cells
machine learning
electronic health record
bone marrow
atrial fibrillation
photodynamic therapy
contrast enhanced
replacement therapy